Almost five years after the creation of the Sacco System business network, today we are glad to communicate the birth of Sacco System Holding srl: a new corporate structure for which the Verga family plans to forge additional group synergies with a view to achieving structured international growth within the next few years.
Currently, the group includes four companies – Caglificio Clerici spa, Sacco srl, Centro Sperimentale del Latte srl, and Kemikalia AB.
With this new corporate structure, it intends to face the challenge of development at an international level, placing itself in the market with an even greater value not only in terms of economic activity and equity, but also of brand and therefore of business.
The increasingly open desire for innovation and international growth has led the owners to implement this new corporate structure without precluding other choices in the future.
With an aggregate turnover of more than 130 million euros, the companies headed by Sacco System Holding srl, have been able to conquer increasingly dominant positions in the market of enzymes, bacteria and probiotic cultures.
The people of Sacco System will continue to be fundamental in achieving the ambitious goals of the next years, positioning themselves in the biotechnology market in a profitable way with an increasingly stronger and more recognizable brand.
Sacco System: International group, Family spirit.
Latest News
An important regulatory goal has been achieved with the conclusion reached by an independent expert panel for the self-affirmed GRAS (Generally Recognized as Safe) determination of our postbiotic CRL1505® HI.
El grupo acelera su estrategia de desarrollo en Sudamérica mediante una doble operación: la adquisición de una empresa uruguaya y la integración total de su filial brasileña. El grupo apunta
La leche es el recurso más valioso en la producción láctea.Solo es posible obtener productos de alta calidad a partir de leche de alta calidad, y en el panorama actual,
“Survivability of probiotic CA15 strain with and without fluconazole co-administration and its effect on gut microbiota and metabolome through SHIME® model” is the title of the study that has been
GRAS (Generally Recognised as Safe) is a designation by the US Food and Drug Administration (FDA) that indicates that a substance is considered safe based on expert consensus or a
Brisbane, 8 January 2025 Sacco System Australia, a leader in innovative probiotic and postbiotic solutions, is proud to announce that L. rhamnosus CRL 1505 HI (heat-inactivated) and Lactobacillus acidophilus LA1
Our commitment to sustainability: a review of an evolving journey We are proud to present the fifth edition of our Sustainability Report, an opportunity to reflect on the milestones achieved
Today in the presence of Luna Angelini Marinucci, from 2022 the Consul of Italy in Brisbane, with territorial jurisdiction over the State of Queensland and over the Northern Territory the
At Sacco System we have always put Sustainability at the very core of our activities and our commitment, which is why we are proud that our companies Caglificio Clerici, Sacco
Indianapolis, Ind., and Yeerongpilly, Queensland, Australia, March 13, 2024 – List Biotherapeutics, Inc. (List Bio) and Sacco System Australia Pty Ltd (Sacco) today announced a lead share agreement to introduce
Sacco System is the international biotechnological company dedicated to the food, nutraceutical, and pharmaceutical industries, based on tradition, expertise, research, and innovation which sells and distributes its ingredients in more
We are proud to announce that Sacco System has made a significant donation in support of Action4Diabetes (A4D), mission—a UK-based charity committed to ensuring free access to crucial medical supplies,